The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.

The IOF highlights the importance of collaborative efforts in treating osteoporosis, ensuring appropriate care globally.

Disruption is a pressing problem in the pharmaceutical world; patient health depends on clinical trial organisers avoiding it ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...

Avacta Therapeutics has entered a strategic collaboration with Tempus AI to advance the development of drugs in oncology.

The European Union's CHMP has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua to treat ATTRv-PN.

GSK has announced a £50m ($54.3m) investment in a partnership with the University of Cambridge to expedite R&D in ...

MangoRx said it has strong arguments against Eli Lilly’s claims. Image credit: Shutterstock / Cynthia A Jackson. MangoRx said ...

Digital transformation is a pressing concern among leading pharma firms. Credit: Gorodenkoff / Shutterstock. IoT, cloud ...